RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet Related: WHO issues emergency use approval for India’s Covaxin. Commentary on Twitter NEW—Interim data from a phase […]
The post RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults. appeared first on Links Medicus.
M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.
Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal
The post M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19. appeared first on Links Medicus.
Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed.
COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR
The post Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed. appeared first on Links Medicus.
Podcast | COVID Updates: The Outpatient Edition.
COVID Updates: The Outpatient Edition – The Curbsiders Commentary on Twitter Who gets a #COVID booster? Can we mix & match vaccines? What are monoclonal antibodies & when should we use them? Shots for kids? Ready yourself to answer these questions & more w/ @MonicaGandhi9 #vaccine #MedEd #FOAMed https://t.co/URrfwtuxVf pic.twitter.com/o26ElbPNaJ — The Curbsiders (@thecurbsiders) […]
The post Podcast | COVID Updates: The Outpatient Edition. appeared first on Links Medicus.
COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.
COVID antiviral pills: what scientists still want to know – Nature Related: [Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see […]
The post COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”. appeared first on Links Medicus.
IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19.
Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19 Commentary on Twitter New recommendation on the use of eye protection as well as revised recommendations and literature on the use of PPE now available in IDSA’s COVID-19 Infection Prevention Guideline: https://t.co/MiACvSoG92#COVID19Guidelines pic.twitter.com/Zp7s0Ely9J — […]
The post IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19. appeared first on Links Medicus.
A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.
A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm – Science Original viewpoint: Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1) – Forbes Related: The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first. Merck to allow other nations to produce new COVID-19 antiviral. […]
The post A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm. appeared first on Links Medicus.
Opinion | Protective immunity after recovery from SARS-CoV-2 infection.
Protective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases Commentary on Twitter "Policy makers should consider recovery from previous SARS-CoV-2 infection equal to immunity from vaccination for purposes related to entry to public events, businesses, and the workplace,or travel requirements" Do you agree with this?I don't #IDtwitter https://t.co/FHbgXILD8Z — Antibiotic Stewa®️x? […]
The post Opinion | Protective immunity after recovery from SARS-CoV-2 infection. appeared first on Links Medicus.
[Preprint] RCT: In hypoxic but not critically ill patients with COVID-19, an intervention to increase prone positioning did not improve outcomes.
RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv Related: RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19. RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care. M-A: Prone positioning of nonintubated […]
The post [Preprint] RCT: In hypoxic but not critically ill patients with COVID-19, an intervention to increase prone positioning did not improve outcomes. appeared first on Links Medicus.
Review: Antineutrophil cytoplasmic antibody-associated interstitial lung disease.
Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review – European Respiratory Review
The post Review: Antineutrophil cytoplasmic antibody-associated interstitial lung disease. appeared first on Links Medicus.